1.
|
Phase: Phase IV Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: TaCyDexVMP7, NCT00652041
|
|
2.
|
Phase: Phase III, Phase II Type: Treatment Status: Completed Age: 19 and over Sponsor: Other Protocol IDs: 01-002-0601, NCT00205751
|
|
3.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: 000080, 00-C-0080, NCI-00-C-0080, NCI-T99-0053, T99-0053, NCT00020085, NCT00004635
|
|
4.
|
Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: ECOG-2898, NCT00005966, E2898
|
|
5.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 to 65 Sponsor: Other Protocol IDs: CKTO-2001-02, HOVON-50MM, EU-20133, HOVON-CKVO-2001-02, NCT00028886
|
|
6.
|
Phase: Phase III Type: Treatment Status: Completed Age: Over 18 Sponsor: NCI Protocol IDs: RTOG-BR-0118, RTOG-DEV-1006, NCT00033254
|
|
7.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000069274, E-E1A00, E1A00, NCT00033332
|
|
8.
|
Phase: Phase III Type: Treatment Status: Completed Age: Not specified Sponsor: NCI Protocol IDs: GOG-0198, NCT00041080
|
|
9.
|
Phase: Phase III Type: Treatment Status: Closed Age: 16 and over Sponsor: NCI, Other Protocol IDs: MY10, CAN-NCIC-MY10, CAN-NCIC-JMY10, ECOG-NCIC-JMY10, CELGENE-CAN-NCIC-MY10, CDR0000258158, NCIC-MY.10, NCT00049673
|
|
10.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: Over 18 Sponsor: Other Protocol IDs: CDR0000302440, LLCG-STUDY-12, EU-20207, ISRCTN16174527, NCT00061919
|
|
11.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: THAL-MM-003, NCT00057564
|
|
12.
|
Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR004579, NCT00097981
|
|
13.
|
Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: UARK 2005-01, NCT00111748
|
|
14.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 to 70 Sponsor: NCI, Other Protocol IDs: 2004.00, NCI-2009-01543, FHCRC-2004.00, 6004, MEDIMMUNE-FHCRC-2004.00, NCT00217438
|
|
15.
|
Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: MCC-13043, CZOL446E, NCT00215943
|
|
16.
|
Phase: Phase III Type: Treatment Status: Completed Age: Not specified Sponsor: Other Protocol IDs: NMSG #12, NFR 90000288, NCT00218855
|
|
17.
|
Phase: Phase III Type: Treatment Status: Completed Age: Under 60 Sponsor: Other Protocol IDs: MM01, NCT00207805
|
|
18.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: EudraCT: 2005-001628-35, EBMT-CLWP: 42206611, NCT00256776
|
|
19.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000530050, P30CA015083, MC0289, 421-03, MAYO-MC0289, MAYO-IRB-421-03, NCT00432458
|
|
20.
|
Phase: Phase III Type: Treatment Status: Completed Age: 66 and over Sponsor: Other Protocol IDs: 2005-001111-21, NCT00443235
|
|
21.
|
Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: THA PH INT 2005 CL 001, NCT00452569
|
|
22.
|
Phase: Phase III Type: Treatment Status: Completed Age: 65 and under Sponsor: Other Protocol IDs: 2005-001110-41, NCT00461747
|
|
23.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: C05009, NCT00507416
|
|
24.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 to 74 Sponsor: Other Protocol IDs: UARK 2006-66, NCT00572169
|
|
25.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Natural history/Epidemiology, Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00522, U10CA021115, CDR0000583984, E1A06, ECOG-E1A06, NCT00602641
|